Calgary, Alberta--(Newsfile Corp. - December 11, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to individuals suffering from vascular dementia, angina, ischemic cardiomyopathy, congestive heart failure, non-ischemic dilated cardiomyopathy, pain, total body ischemia, peripheral arterial disease and chronic limb threatening ischemia, is pleased to announce that Thomas Smeenk, BA, has published a major theoretical manuscript introducing the Conformal Consciousness Hypothesis (CCH) — a mathematically grounded framework proposing a new conformal invariant with the potential to link General Relativity, Quantum Mechanics, Cosmology, and String Theory.

The paper, titled "Toward Einstein's Missing Principle: Foundations of the Conformal Consciousness Hypothesis," explores the idea that a simple, dimensionless ratio, A = E/hν may serve as a relational constant of nature. If correct, the existence of such an invariant could offer a conceptual bridge across physics' deepest divides — a problem that has resisted unification for more than a century.

"Physics has remarkable theories, but no single relational principle that ties them all together," said Thomas Smeenk. "CCH does not claim a final unification, but it proposes an invariant that may guide us toward the deeper relational principle long pursued by Einstein and generations of physicists."

The manuscript includes mathematical appendices demonstrating how the invariant behaves under conformal transformations — mappings that preserve relational structure while discarding absolute scale — and explores implications for Penrose's Conformal Cyclic Cosmology, non-computability, quantum entanglement, and string-theory vibrational modes.

A Moment of Insight Under the Night Sky

Reflecting on the paper's origins, Smeenk shared:

"I was deeply moved by Sir Roger Penrose's Nobel Lecture, particularly his closing remarks on conformal cyclic cosmology ("CCC"). Penrose often asks himself, 'What do I understand in general relativity that others may not see yet?' and then follows the geometry to where it leads."

"One night on my deck, looking into the stars, I asked: 'What do I understand about the universe that might be worth expressing mathematically?' Alan Watts' line came to mind: 'Just as the tree apples, the Earth peoples.' I said aloud: 'The universe consciousnesses — and I am aware of it…I am an example of the universe aware of itself!' If awareness arises from the universe itself, I wondered, is there a mathematical equation that reflects this relationship that survives Penrose's CCC? Pursuing that question led directly to the mathematics that emerged from my intuition," Smeenk said.

Relevance to Hemostemix and Investor Interest

While the Conformal Consciousness Hypothesis is a theoretical physics contribution, Smeenk's insight reflects the same analytical discipline, creativity, and systems-level thinking he applies to Hemostemix's commercialization strategy.

Hemostemix is commercializing VesCell, ACP-01, as a treatment for conditions of ischemia, expanding pathways enabled by the evolving regulatory frameworks in Florida, The Bahamas, and Canada.

"Innovation is a mindset," Smeenk said. "Whether one is building a commercialization rollout, designing a basket clinical trial wherein patients can pay to be treated and followed, or exploring the foundations of physics, the discipline is the same: follow the evidence, test hypotheses, and let the mathematics guide you. We are using the best laid path to gain velocity while looking at commercialization structures others may have missed," Smeenk said.

Investors increasingly seek leadership that combines scientific imagination with operational execution. Smeenk's publication strengthens Hemostemix's profile as a company guided by a CEO capable of both advanced theoretical insight and disciplined commercial development.

The manuscript Toward Einstein's Missing Principle: Foundations of the Conformal Consciousness Hypothesis is also available at ConformalConsciousness.com.

ABOUT HEMOSTEMIX

Hemostemix is an autologous stem cell therapy platform company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed, patented, is scaling and selling autologous (patient's own) blood-based stem cell therapy, VesCell™ (ACP-01). Hemostemix has completed seven clinical studies of 318 subjects and published its results in eleven peer reviewed publications. ACP-01 is safe, clinically relevant and statistically significant as a treatment for peripheral arterial disease, chronic limb threatening ischemia, non ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. Hemostemix completed its Phase II clinical trial for chronic limb threatening ischemia and published its results in the Journal of Biomedical Research & Environmental Science. As compared to a five year mortality rate of 50% in the CLTI patient population, UBC and U of T reported to the 41st meeting of vascular surgeons: 0% mortality, cessation of pain, wound healing in 83% of patients followed for up to 4.5 years, as a midpoint result. For more information, please visit www.hemostemix.com.

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to the Conformal Consciousness Hypothesis, and Phase I basket protocol clinical trial of ACP-01 as a treatment for multiple indications of ischemia including Vascular Dementia, and the treatment of pain in Florida related related to angina, peripheral arterial disease, chronic limb threatening ischemia, ischemic cardiomyopathy, non-ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia with Angiogenic Cell Precursors (ACP-01) in furtherance of sales of VesCell™ (ACP-01), and the commercialization of ACP-01 via the sale of compassionate treatments under Florida SB 1768. There can be no assurance that such forward-looking information will prove to be accurate. Actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable. These assumptions include, but are not limited to: the underlying value of Hemostemix and its Common Shares; the successful resolution of any litigation that Hemostemix is pursuing or defending (the "Litigation"); the results of ACP-01 research, trials, studies and analyses, including the analysis being equivalent to or better than previous research, trials or studies; the receipt of all required regulatory approvals for research, trials or studies; the level of activity, market acceptance and market trends in the healthcare sector; the economy generally; consumer interest in Hemostemix's services and products; competition and Hemostemix's competitive advantages; and, Hemostemix obtaining satisfactory financing to fund Hemostemix's operations including any research, trials or studies, and any Litigation. Forward-looking information is Subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the ability of Hemostemix to complete clinical trials, complete a satisfactory analyses and file the results of such analyses to gain regulatory approval of a phase II or phase III clinical trial of ACP-01; potential litigation Hemostemix may face; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations including the actual results of future research, trials or studies; competition; changes in legislation affecting Hemostemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in Hemostemix's markets and the markets in which it expects to compete; lack of qualified, skilled labour or loss of key individuals; and risks related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, disruptions to economic activity and financings, disruptions to supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession or depression; the potential impact that the COVID-19 pandemic may have on Hemostemix which may include a decreased demand for the services that Hemostemix offers; and a deterioration of financial markets that could limit Hemostemix's ability to obtain external financing. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Hemostemix's disclosure documents on the SEDAR website at www.sedarplus.ca. Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, it is Subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/277729